Minerva Neurosciences | NERV - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Adma Biologics USD 665.18M 40.94M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
AstraZeneca USD 114.02B 59M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Cipla INR 424.96B 23.32B 2026-03
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 145.86M 10.71M 2026-03
CSL USD 37.9B 1.5B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
J&J USD 201.06B 167M 2026-06
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novavax USD 1.04B 133.35M 2026-03
Pfizer USD 207.62B 542M 2026-03
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 128.02B 1.22B 2026-03
Takeda JPY 15.45T 44.34B 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12